Idience's Venadaparib Research Published in AACR Journal 0'
Idience, a subsidiary of Il-Dong Pharmaceutical Group specializing in new drug development, announced on the 7th that its preclinical research findings on venadaparib (development code IDX-1197) have been published in the latest issue of the journal 'Molecular Cancer Therapeutics'.
'Molecular Cancer Therapeutics' is an academic journal published by the American Association for Cancer Research (AACR) and focuses on translational research in oncology. The research paper on venadaparib was highlighted in the journal's editor's section due to the innovation and potential of the new drug candidate, as noted by the editors.
Venadaparib is an oral targeted anticancer drug candidate that inhibits PARP (Poly ADP-ribose polymerase). The highlighted section of the journal describes venadaparib as a next-generation PARP inhibitor with excellent anticancer effects and no significant side effects or harmful impacts in toxicity studies.
According to the research paper, venadaparib demonstrated superior anticancer efficacy compared to first-generation PARP inhibitors like olaparib and was selectively effective against cancers with BRCA (breast cancer susceptibility gene) mutations.
In in vivo studies modeling ovarian, breast, and pancreatic cancers, venadaparib showed more potent anticancer effects at relatively lower doses compared to olaparib.
Idience stated, "Venadaparib is selectively toxic to cancer cells, improving hematological safety compared to first-generation PARP inhibitors. It is expected to expand its use and indications through combination therapies with various anticancer drugs as a next-generation PARP inhibitor."
Idience was established in 2019 as a subsidiary of Il-Dong Holdings, the holding company of Il-Dong Pharmaceutical Group, to focus on the clinical development of anticancer drug candidates including venadaparib.
Venadaparib is currently undergoing Phase 1b/2 clinical trials as a monotherapy in Korea, and Phase 1b clinical trials for combination therapy for gastric cancer in Korea, the United States, and China.
